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THIOPENTAL IN LETHAL INJECTION
Susi Vassallo, M.D.*
I. INTRODUCTION
In the United States, the current protocols for execution by le-
thal injection call for the administration of the combination of
three drugs: the anesthetic thiopental, a barbiturate;' the para-
lyzing agent, pancuronium bromide; and potassium chloride, the
drug that interrupts electrical cardiac conduction. States differ in
the doses and methods of administration; however, the most com-
mon dosing regimens call for the administration of a sequence of
intravenous drugs by bolus administration; first, a single injection
of two to five grams of thiopental; next, an injection of sixty milli-
grams of pancuronium bromide; finally, an injection of 240 millie-
quivalents of potassium chloride, or less, depending on the
protocol.
An inmate must be unconscious in order to avoid the sensation
of suffocation from paralysis caused by the second drug, or the
pain caused by the intravenous infusion of concentrated potassium.
A critical question in this regard is whether the dose and method of
administration of thiopental is adequate to reliably render the in-
mate unconscious until death occurs.
On January 7, 2008, the United States Supreme Court heard oral
arguments in Baze v. Rees.2 One of the issues raised is whether the
procedures in place are capable of adequately assuring successful
administration of death to meet the constitutional standards of the
Eighth Amendment. An important part of the argument rested on
* Susi Vassallo, M.D., F.A.C.E.P., F.A.C.M.T.; Faculty, New York University
School of Medicine, Department of Emergency Medicine and the New York Regional
Poison Control Center. Thank you to Mary Ann Howland, PharmD. for her helpful
examination of the pharmacodynamics of thiopental; Rama Rao, M.D. for her analy-
sis; and Nancy Homsher, law librarian, for her expertise. Many thanks to my editor,
Conor Mcdonough, for his excellent work.
1. Barbiturates are a class of drugs that causes central nervous system depres-
sion. They are derivatives of barbituric acid. J. G. Reves et al., Intravenous Nonopioid
Anesthestics: Barbiturates, in MILLER'S ANESTHESIA 326 (Ronald D. Miller, ed., 6th
ed. 2005).
2. Baze v. Rees, No. 07-5439, 2008 WL 63222 (U.S. argued Jan. 7, 2008). Baze, a
case brought by two Kentucky death row inmates, challenges the state's lethal injec-
tion protocol as well as questions what the appropriate standard should be for lower
courts to apply to assess whether the Eighth Amendment's prohibition against cruel
and unusual punishment has been violated.
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the qualities and attributes of the anesthetic thiopental. Mr. Ver-
rilli, counsel for the petitioner, conceded that if the dose of the
anesthetic thiopental was "always" properly administered into the
condemned inmate there would be no "risk."3 In other words, the
inmate would not suffer the terror of suffocation or the pain of
intravenous potassium chloride. Of course, he continued, there
could be no guarantee and one could not assure successful adminis-
tration of the thiopental unless proper monitoring was involved.
Justice Scalia quickly pointed out that medical doctors cannot par-
ticipate in executions according to the ethics guidelines of the
American Medical Association, and therefore could not serve as
monitors.4 At this point in the testimony, Mr. Verrilli put forth a
highly contentious assertion that thiopental alone was an alterna-
tive method of lethal injection:
Well, Your Honor, of course, that's why there is another practi-
cal alternative here, which solves that problem, which is the sin-
gle dose of barbiturate, which does not require the participation
of a medically trained professional. . . . [T]hiopental is a barbit-
urate and by definition will inflict death painlessly. The record
in this case establishes-each expert, the Petitioner's expert and
Respondents' expert, testified that it is guaranteed at the three
gram dose to cause death.5
Later, Chief Justice Roberts inquired, "that method has never
been tried, correct?" Mr. Verrilli replied, "Well, it has never been
tried on humans. That is correct."6 Interrupted at that point, it is
left to speculation what Mr. Verrilli would have said had he been
allowed to continue. Mr. Verrilli is correct that sodium thiopental
is unstudied as a single killing agent for humans. It is also not the
agent of choice in animal euthanasia. It is sodium pentobarbital
that is most commonly used to euthanize animals.7
The proposal of a single drug protocol using thiopental as an ef-
fective new method of execution by lethal injection, and the basis
on which that proposal is put forth, namely, Mr. Verrilli's invoca-
tion of the testimony of the medical experts on both sides of the
arguments in Baze v. Rees, demands scrutiny. It is highly unlikely
that the medical experts in Baze, Mark Dershwitz, M.D., testifying
3. Transcript of Oral Argument at 5, Baze, No. 07-5439, 2008 WL 63222 (argued
Jan. 7, 2008) [hereinafter Baze Transcript].
4. Id. at 6.
5. Id. at 6, 8.
6. Id. at 9.
7. Am. Veterinary Ass'n., 2000 Report on the AVMA Panel on Euthanasia, 218 J.
AM. VETERINARY MED. ASS'N 5 (2001).
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for the state, and Mark Heath, M.D., testifying on behalf of the
plaintiffs, intended to testify that thiopental would serve as an ef-
fective single killing agent or to establish thiopental as a new single
dose lethal injection protocol. In multiple challenges to lethal in-
jection at the state level, the overwhelming majority of expert testi-
mony by Dr. Dershwitz and Dr. Heath concerned thiopental's
ability to assure a state of unconsciousness of adequate duration
and depth to last until cardiac arrest occurred, most likely from the
potassium chloride.8 Thiopental is not the agent of death in the
current lethal injection protocol. The amicus brief submitted by
the American Society of Anesthesiologists states, "there is no dis-
pute that a massive or supraclinical dose of thiopental (as those
being considered by the courts), if effectively delivered into the cir-
culation, will reliably produce prolonged and deep unconscious-
ness."9 Nowhere does the amicus brief address the lethality of
thiopental alone.' ° However, in the Netherlands where euthanasia
is legal when certain conditions are met," the use of intravenous
thiopental to induce death is addressed. In order to educate physi-
cians and pharmacists regarding the requirements and recommen-
dations for substances used in euthanasia, The Royal Dutch
Society for the Advancement of Pharmacy designated a task force
which issued the "Report on Euthanasic Agents" in 1987. The re-
port, updated in 1994, concluded that it is not possible to adminis-
ter enough thiopental intravenously to guarantee a lethal effect. 2
Studies of thiopental have never been performed using the same
dosing or administration regimens as are followed in the current
lethal injection protocols. Nonetheless, this Article addresses
whether there is adequate scientific evidence on which to base a
new single drug protocol using thiopental alone as was recom-
mended to the Supreme Court as a "practical alternative" to the
current three-drug protocol.13
8. The exact cause of death has been questioned in some executions. See Teresa
A. Zimmers, Lethal Injection for Execution: Chemical Asphyxiation?, 4 Pus. Li-
BRARY SCI. MED. e156, 0647 (2007) (noting that the addition of potassium chloride to
a lethal injection protocol in North Carolina was not associated with a statistically
significant increase in the speed of death).
9. Brief for American Society of Anesthesiologists as Amicus Curiae Supporting
Neither Party, Baze v. Rees, No. 07-5439, 2008 WL 63222 (U.S. argued Jan. 7, 2008).
10. Baze Transcript, supra note 3, at 7.
11. Agnes van der Heide et al., End of Life Practices in the Netherlands Under the
Euthanasia Act, 356 NEW ENG. J. MED. 1957, 1958 (2007).
12. ROYAL DUTCH Soc'Y FOR THE ADVANCEMENT OF PHARMACY, ADMINISTRA-
TION AND COMPOUNDING OF EUTHANASIC AGENTS (1994).
13. Baze Transcript, supra note 3, at 7.
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II. DIFFICULTIES INVOLVED WITH USING SCIENTIFIC DATA
DERIVED FROM THIOPENTAL STUDIES
This Part reviews general studies of thiopental and highlights the
limitations of these studies as they relate to lethal injection.
A first issue in the analysis of the scientific literature on the use
of thiopental is the method of administration of thiopental. The
pharmacodynamic effect'4 of thiopental varies with the method of
administration, either by a single intravenous bolus 15 (such as is the
case in lethal injection in almost all states) or by continuous intra-
venous infusion. Dr. A. Jay Chapman, chief medical examiner for
the state of Oklahoma, recognized this variance when he suggested
a continuous infusion of thiopental as one of his recommendations
for the first lethal injection protocol for the state of Oklahoma. 16 If
the published studies on thiopental rely on a different means of
administration than lethal injection protocols, then it is difficult
and/or inappropriate to draw predictions from these studies to the
lethal injection context.
Secondly, the total dose of thiopental used 17 in published studies
should be comparable to the doses used in lethal injection. Most
studies using thiopental administer smaller amounts of thiopental
than those doses used in lethal injection.'8 Even in studies, how-
ever, where the total dose of thiopental administered appears com-
parable to the total dose administered during lethal injection, the
method of administration differed. Administration of thiopental in
14. The term "pharmacodynamic" refers to the effects of the drug in the body.
15. A bolus injection is a single push on the plunger of the syringe so the drug is
delivered over seconds. For example, if 5 grams of thiopental is put into a 60 milliliter
(ml) syringe and can be delivered at 2 ml per second, it will take 30 seconds to deliver
the drug if there are no difficulties such as resistance to flow in the intravenous line.
16. Deborah W. Denno, The Lethal Injection Quandary: How Medicine Has Dis-
mantled the Death Penalty, 76 FORDHAM L. REV. 49 (2007) [hereinafter Denno, Le-
thal Injection Quandary].
17. The total dose of thiopental is best expressed as the number of milligrams of
thiopental per kilograms of body weight of the subject, or "mg/kg."
18. The doses of thiopental used in lethal injection protocols range from 2 to 5
grams. The dose is not based on a milligram per kilogram body weight basis. De-
pending on the size of the inmate and the protocol, the dose ranges from 6.6 to 75 mg/
kg. See Zimmers, supra note 8, at 0649. In comparison, clinical induction doses rang-
ing from 2-15 mg/kg are described in the article by Toner. W. Toner et al., Another
Look at Acute Tolerance to Thiopentone, 52 BRIT. J. ANAESTHESIA 1005 (1980) (citing
John W. Dundee, Henry L. Price & Robert D. Dripps, Acute Tolerance to Thi-
opentone in Man, 28 BRIT. J. ANAESTHESIA 344 (1956)). Brodie infused from 43-67
mg/kg thiopental in four subjects, but did so over time. See Bernard B. Brodie et al.,
Acute Tolerance to Thiopental, 102 J. PHARMACOLOGY & EXPERIMENTAL THERAPEU-
TICS 215, 215 (1951) [hereinafter Brodie et al., Acute Tolerance]. This stands in con-
trast to the rapid bolus injection frequently used during lethal injection.
960 [Vol. XXXV
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these studies is usually by continuous intravenous infusion or by
repeated bolus injection over some extended period of time, and
not by a single intravenous bolus as is used in the lethal injection
context. Thus, as stated above, although the dose of thiopental
may appear comparable between these clinical studies and com-
mon lethal injection protocols, the pharmacodynamics are likely to
differ because of the differences in the means of administering
thiopental. Therefore, the conclusions of such studies do not apply
in lethal injection.
A third issue facing comparisons between studies of thiopental
and lethal injection protocols is that thiopental concentrations are
not directly measured in the brain. Instead, thiopental concentra-
tions are measured in an easily obtainable tissue such as blood,
plasma, 19 or fat. Subsequently, mathematical derivations are ap-
plied to estimate the brain thiopental concentration.2 0 The short-
coming of this approach is that the concentration of thiopental in
one tissue source does not necessarily reflect the other, and may
not reflect the clinical condition of the individual.21  In other
words, the plasma or blood concentration of thiopental does not
necessarily reflect the level of sedation in the brain.2 2 To summa-
rize, thiopental drug concentrations obtained from different sites,
such as plasma, do not reflect the physiological consequences at the
site of interest, such as the brain.23
19. Plasma is the liquid portion of blood after centrifugation removes the blood
cells.
20. Debra A. Schwinn & Steven L. Shafer, Basic Principles of Pharmacology Re-
lated to Anesthesia, in MILLER'S ANESTHESIA, supra note 1, at 67
21. Bernard B. Brodie et al., The Fate of Thiopental in Man and a Method for Its
Estimation in Biological Material, 1 J. PHARMACOLOGY & EXPERIMENTAL THERA-
PEUTICS 85, 93-94 (1950) [hereinafter Brodie, Fate of Thiopental] (noting that in ca-
nine subjects, significant portions of thiopental administered intravenously is stored in
fat, and indicating that to "what extent [thiopental] content of each tissue depends on
the proportion of fat is now under study").
22. See Dundee, Price & Dripps, supra note 18, at 350 ("These observations show
that there is a wide variation in the blood [thiopental] levels at which normal patients
awake from the doses of the drug used in clinical anaesthesia. The blood [thiopental]
level thus is not a reliable guide to the depth of anaesthesia."); Brodie et al., Acute
Tolerance, supra note 18, at 216 (noting a statistically significant difference in the
plasma levels of thiopental at the time of recovery of normal patients and suggesting
that tolerance to thiopental might account for this variation).
23. Thomas K. Henthorn, Michael J. Avram & Tom C. Krejcie, Intravascular Mix-
ing and Drug Distribution: The Concurrent Disposition of Thiopental and Indocy-
anine Green, 45 CLINICAL PHARMACOLOGY & THERAPEUTICS 56, 62 (1989) (noting
that kinetic models of distribution of thiopental indicate multiple physiological com-
partments with varied kinetic features and that the equilibration of thiopental be-
tween these compartments and the blood is not clearly equivalent).
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Finally, there are studies of thiopental that apply
pharmacokinetic-pharmacodynamic parameters and combine infu-
sion quanta 24 dose-response data.25 In some studies, these models
are used to predict a clinical endpoint such as loss of consciousness.
The ability to accurately predict thiopental dose-response relation-
ships (the loss of consciousness at a certain dose of thiopental)
through computer modeling demands many values for thiopental
doses derived from average populations of young healthy men.
Average population-based values for pharmacokinetic parameters,
drug administration rate, and derived rate constants quantifying
concentrations in various tissue compartments, may not reflect the
physiology of an individual inmate. 26 The data used to estimate
these population-based parameters derive largely from studies in
healthy men devoid of premedication with benzodiazepines or
opiates in the acute prestudy period.2 7 Use of other centrally-act-
ing drugs excluded these men from the study.28 Age, cardiac out-
put, body weight, or lean body mass, were all-important
determinants of thiopental dose requirements in one such study. 29
In dogs, obesity affected model predictions of plasma thiopental
concentrations.30 In another study, the observed effective dose of
thiopental needed to achieve the chosen end-point, of loss of con-
sciousness, increased significantly with increasing infusion rates.31
There was a thirteen percent error in the predictions based on one
model at the higher infusion rates.32 As stated in a recent paper,
physiologically-based models, while useful in explaining some fac-
tors of thiopental disposition using model simulation, are too com-
24. Quantal: the plural of quantus, Latin for "how many", signifies two experi-
mental alternatives i.e. response or no response.
25. See Colin A. Shanks, A Pharmacokinetic-Pharmacoldynamic Model for Quan-
tal Responses with Thiopental, 21 J. PHARMACOKIN. BIOPHARMACEU. 309 (1993).
26. W. Brooks Gentry et al., Effect of Infusion Rate on Thiopental Dose-Response
Relationships, 81 ANESTHESIOLOGY 316 (1994).
27. Michael J. Avram et al., Determinants of Thiopental Induction Dose Require-
ments, 76 ANESTHESIOLOGY & ANALGESIA 10, 10-11 (1993); Gentry et al., supra note
26, at 317 ("Patients chronically using central nervous system active drugs ... were
excluded from the study as were patients receiving either benzodiazepines or opiates
acutely ... .
28. Id.
29. Avram et al., supra note 27, at 11.
30. Michael Weiss, Tom C. Krejcie & Michael J. Avram, A Minimal Physiological
Model of Thiopental Distribution Kinetics Based on a Multiple Indicator Approach, 35
DRUG METABOLISM & DISPOSITION 1525 (2007).
31. Gentry et al., supra note 26, at 319.
32. Id.
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plex to be applied to plasma concentration-time data.33 Currently,
the shortcomings of modeling studies limit their utility in under-
standing thiopental in execution by lethal injection. New modeling
methods continue to be developed to further define the action of
thiopental in the clinical setting.34
A. Continuous Infusion Studies of Thiopental
Many studies of thiopental are performed by administering thio-
pental by short continuous infusion or by repeated boluses over
time.35 Short continuous infusion of thiopental results in a model
that does not mimic the single bolus injection of thiopental in lethal
injection protocols.36 Models, studies, and clinical scenarios where
repeated bolus injections are given, or short or continuous infu-
sions are administered, do not equate to the situation in lethal in-
jection where a single bolus injection is administered. For
example, the long continuous infusions used to maintain coma in
brain-injured patients for many hours to days, and the attendant
large doses of thiopental, result in steady state conditions.37 This
situation has no relationship to the single bolus injection used dur-
ing execution.38
In one continuous infusion study in humans using doses of thio-
pental comparable to the total doses used in lethal injection, doses
of 2.3 grams were administered intravenously over 25 minutes.39
33. See Weiss, Krejcie & Avram, supra note 30.
34. Id.
35. Hl61ne Russo & Franqoise Bressolle, Pharmacodynamics and Pharmacokinet-
ics of Thiopental 35 CLINICAL PHARMACOKINETICS 95, 107 (1998) (describing the dif-
ferences on dosage requirements as a function of infusion rate).
36. Deborah W. Denno, When Legislatures Delegate Death: The Troubling Para-
dox Behind State Uses of Electrocution and Lethal Injection and What It Says About
Us, 63 OHIO ST. L.J. 63, 207-60 (2002) [hereinafter Denno, When Legislatures Dele-
gate] (describing the lethal injection protocols of several states which in some in-
stances rely on bolus injection).
37. Ian L. 0. Buxton, Pharmacokinetics and Pharmacodynamics: The Dynamics
of Drug Absorption, Distribution, Action and Elimination, in Goodman and Gilman's
the Pharmacological Basis of Therapeutics, 1 (Laurence L. Brunton et al. eds., 11th
ed. 2006).
38. Dyal C. Garg et al., Pharmacokinetics of Thiopental in the Asphyxiated Neo-
nate, 11 DEV. PHARMACOL. THER. 213, 214 (1988); Donald R. Stanski et al.,
Pharmacokinetics of High-Dose Thiopental Used in Cerebral Resuscitation, 53 ANES-
THESIOLOGY 169, 171 (1980) (noting a change in kinetics of thiopental elimination
from circulation between single-bolus and continuous infusion administration); Alain
Turcant et al., Thiopental Pharmacokinetics Under Conditions of Long-Term Infusion,
63 ANESTHESIOLOGY 50, 53-54 (1985).
39. See Brodie et al., Acute Tolerance, supra note 18, at 215.
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Larger doses of 3.9 grams were administered over 50 minutes.40 In
the study, four male study subjects received 3.3 to 3.9 grams, or 43
to 67 mg/kg, of thiopental by continuous infusion.41 Anesthesia,
defined by the "conjunctival reflex and eyeball motion, 42 lasted
from four to five hours.43 Awakening, arbitrarily defined as the
ability of the study subject to stick out his tongue, occurred at
plasma concentrations of 16.8 to 32.6 mg/L.44 Interestingly, as the
dose of thiopental increased, the plasma concentration of thiopen-
tal at awakening was increased, such that the blood concentrations
of thiopental at awakening were sixty-seven percent higher follow-
ing the high doses of thiopental than after the small doses.45 In
their discussion, the authors concluded that the central nervous
system's response to thiopental may have depended on the initial
peak concentration, or the length of time thiopental persisted in
the brain.46 The authors called this "acute tolerance", and they of-
fered several possible explanations, including increased drug me-
tabolism, or altered permeability of the blood-brain barrier 47 to the
drug. The most likely mechanism, according to the authors, was
some sort of tissue adaptation refractory to the depressant effects
of thiopental in the brain.4 8 Other authors concluded that acute
tolerance is present49 but some have questioned its origins; one hy-
pothesized that acute tolerance may simply reflect the differences
in thiopental concentrations measured at different sampling sites,
i.e. the peripheral blood vessel versus a more central blood vessel
such as the jugular vein, bringing blood directly from the brain
back to the heart. 0
The authors writing about acute tolerance shared the conclusions





44. Id. at 216.
45. Id. at 217.
46. Id.
47. The blood-brain barrier is a collection of cells tightly formed around the brain
blood vessels that forms an interface between the blood and the brain, limiting the
passage of molecules with certain physiochemical characteristics.
48. See Brodie et al., Acute Tolerance, supra note 18, at 217-18.
49. Robert J. Hudson et al., A Model for Studying Depth of Anesthesia and Acute
Tolerance to Thiopental, 59 ANESTHESIOLOGY 301 (1983).
50. See Dundee, Price & Dripps, supra note 18, at 47 (noting that differences in
thiopental concentrations are not different between the brachial artery and the jugu-
lar vein, but that there might be some difference between arterial and venous blood in
more distal sites, such as the forearm); Toner et al., supra note 18, at 1005.
[Vol. XXXV964
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anesthesia, and isolated plasma thiopental levels are meaningless.5 1
This is important in the lethal injection debate for two reasons;
first, post-mortem studies using peripheral plasma measurements
as a means of establishing level of consciousness at the time of
death are meaningless; second, the literature is replete with studies
demonstrating that plasma thiopental levels do not correlate with
level of consciousness. 5 2
B. Estimating Brain Thiopental Concentrations and Sedation
Many studies of thiopental used limited tissue samples such as
blood or plasma to create a hypothetical mathematical model to
predict the duration and depth of sedation. In the classic article by
Price, six patients were studied preoperatively.53 One or two doses
of 50-100 mg thiopental were administered for anesthesia for the
placement of catheters into the carotid artery and jugular vein. 54 A
single injection of 150-350 mg of intravenous thiopental was then
administered. A thiopental brain concentration was estimated by
simultaneously measuring the flow rate of blood and the difference
between the concentration of thiopental in blood going into the
brain (the carotid artery) and the concentration of thiopental in
blood coming from the brain (jugular vein). 56 Based on calcula-
tions, the brain showed rapid uptake of thiopental such that the
peak brain concentrations occurred less than one minute after the
end of the intravenous injection. 7 After the first minute, however,
the brain concentration of thiopental began to decline and the cal-
culated brain concentrations decreased. 58 At the end of five min-
utes, only approximately forty percent of the total intravenous
51. R.L. Barratt, G.G. Graham & T.A. Torda, Kinetics of Thiopentone in Relation
to the Site of Sampling, 56 BRIT. J. ANAESTHESIA 1385 (1984).
52. See, e.g., Leonard Brand et al., Lack of Correlation Between Electroencepha-
lographic Effects and Plasma Concentrations of Thiopentone 33 BRIT. J. ANAESTHE-
SIA 92 (1981).
53. Henry L. Price et al., The Uptake of Thiopental by Body Tissues and Its Rela-
tion to the Duration of Narcosis 1 CLINICAL PHARMACOLOGY & THERAPEUTICS 16
(1960).
54. Id. at 17. The carotid artery is the major artery bringing blood from the heart
to the brain. The jugular vein is the major vein draining the brain of blood and carry-
ing the blood back to the heart.
55. Id.
56. Id. at 19-20.
57. Id. at 21 fig.3. This figure represents the calculated thiopental concentrations
based on kinetic data that the authors had obtained empirically. In the figure, the





dose of thiopental remained in the brain according to the calcula-
tions.59 The authors concluded that this decrease in brain thiopen-
tal represented the rapid redistribution of thiopental from the
brain to other different body tissues, primarily the muscle and later
on, fat.6° The calculated concentration values for various tissues
were compared with actual measurements of thiopental concentra-
tions from fat and muscle taken during surgical procedures. 61 The
measured decrease in brain thiopental concentration in human pa-
tients mirrored the calculated results: the concentration of thiopen-
tal in the brain dropping from approximately fourteen percent of
the total dose at one minute after infusion to approximately one
percent after one hour. Therefore, the duration of sedation from
thiopental after a single intravenous injection was limited by the
distribution of thiopental out of the brain to lean body tissues.
There are models of the distribution and elimination of thiopental
using a compartmental system where body tissues are grouped
based on similar characteristics of blood perfusion and drug
solubility.62
C. Physiologic and Pharmacodynamic Models
Further studies on thiopental are mathematical models never
validated on animals or humans. In the article by Price discussed
in the section above, the textbook figures63 showing distribution of
thiopental in body tissues over time is based on a mathematical
equation and physiological assumptions. It uses data from a single
dose and applies a mathematical equation to predict the percent of
dose in the tissues at various times after administration. 64
In another example of mathematical modeling, Dr. Mark
Dershwitz has constructed several graphs to demonstrate hypothet-
ical concentrations of thiopental in the blood at various times after
thiopental administration. In expert testimony, Dr. Dershwitz uses
blood thiopental levels to predict the probability of conscious-
59. See id.
60. Id. at 21.
61. Id.
62. See Henthorn, Avram & Krejcie, supra note 23; Russo & Bressolle, supra note
35.
63. Robert J. Fragen & Michael J. Avram, Barbiturates, in MILLER'S ANESTHESIA,
211-15 figs 8-4, 8-8 (Ronald D. Miller ed. 5th ed. 2000)
64. See Price et al., supra note 53; Henry L. Price, A Dynamic Concept of the
Distribution of Thiopental in the Human Body, 21 ANESTHESIOLOGY. 40 (1960).
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ness.65 The graphs assume a steady state infusion of thiopental and
have not been validated in living subjects. The pitfalls of using
thiopental blood concentrations to predict level of consciousness
have been addressed in multiple scientific articles.66 Despite the
lack of validation by peer review, or demonstration of the appro-
priateness of generalization of the data to the situation in lethal
injection, these graphs have repeatedly been introduced into court
during legal arguments concerning lethal injection.
III. CONCLUSION
As a whole, these studies suggest that brain concentrations of
thiopental peak early after intravenous administration, and, even
in the setting of a continuous infusion, have unpredictable effects
on depth and duration of sedation. 67 Although it may be that thio-
pental must induce and maintain unconsciousness for the duration
of the process execution by lethal injection, there is no scientific
study to that effect. The mathematical modeling and lack of vali-
dation studies in living subjects further limit the interpretation of
the data. Finally, none of these studies addresses lethality.
The current lethal injection protocol as created by Dr. A. Jay
Chapman years ago, was accepted without scientific review. 68 To-
day, recommendations for new strategies for lethal injection con-
tinue. A future "improved" method of lethal injection-using
thiopental alone, no longer requiring the participation of medically
trained professionals, and monitoring the depth of anesthesia using
the bispectral index,69 -is an illusion. In a recent article, monitor-
ing of awareness during anesthesia using the bispectral index did
not reduce the frequency of intraoperative awareness. 70 An ac-
companying editorial commentary is relevant to the subject at
hand. In it, the authors warned against the adoption of new de-
vices and interventions without peer-reviewed data, and advised
65. Declaration of Dr. Mark Dershwitz, M.D., Ph.D., $ 4-14, Beardslee v. Wood-
ford, No. 5:04CV05381, 2004 WL 5537989 (N.D. Cal 2005); Affidavit of Dr. Mark
Dershwitz, M.D., Ph.D., $$ 4-14, Johnston v. Crawford, No. 4:04cv1075, 2005 WL
1474022 (E.D. Mo. 2005); Affidavit of Mark Dershwitz, M.D., Ph.D., T$ 4-15, Perkins
v. Beck, No. 5:04-CT-643-BO, 2004 WL 5003233 (N.D. Cal. 2004).
66. See supra notes 50-54 and accompanying text.
67. See supra notes 55-61 and accompanying text.
68. See Denno, Lethal Injection Quandary, supra note 16, at 66-70; Denno, When
Legislatures Delegate, supra note 36, at 90-120.
69. A bispectral index is a computerized monitor of brain function.
70. See Michael S. Avidan et al., Anesthesia Awareness and the Bispectral Index,
358 NEw ENG. J. MED. 1097 (2008).
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that strategies that "intuitively appear to be valuable fail to per-
form as predicted."'"
The history of the development of the three-drug lethal injection
protocol, the problems associated with its administration today, as
well as the characteristics of thiopental, should serve to caution
against the acceptance of a new lethal injection protocol relying on
thiopental alone.
71. See Beverley A. Orser, Depth-of-Anesthesia Monitor and the Frequency of In-
traoperative Awareness, 358 NEw ENG. J. MED. 1189, 1190 (2008).
[Vol. XXXV968
